Study on efficacy and safety of aggressive antihypertensive therapy and its effect on QO
Phase 4
- Conditions
- Hypertension
- Registration Number
- JPRN-UMIN000002918
- Lead Sponsor
- Saga hypertension treatment study group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with secondary hypertension 2) Patients with cardiac failure (NYHA grade III or IV) 3) Pregnant patients, including one trying to conceive pregnancy during the planned study period 4) Patients with severe liver dysfunction 5) Patients with renal failure (serum creatinine ≥2.0 mg/dL) 6) Patients with a history of hypersensitivity to ingredients of losartan or HCTZ 7) Patients with a history of hypersensitivity to thiazide or thiazide-like diuretics 8) Patients who are considered not eligible for the study by the attending doctor due to medical reasons
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in office systolic blood pressure at 3 months after study initiation.
- Secondary Outcome Measures
Name Time Method - Change in office systolic blood pressure (excluding change at 3 months after study initiation), office diastolic blood pressure, home systolic blood pressure, and home diastolic blood pressure at 1, 2, 3, 6, 9 and 12 months after study initiation, and % of patients who achieved the target blood pressure - Change and % change in EQ-5D and scores in the hypertension questionnaire at 3 and 12 months after study initiation - Change and % change in blood glucose levels, serum potassium, serum uric acid, serum creatinine, serum cystatin-C, BNP and RLP-C at 3 and 12 months after study initiation